Baseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT)
Byrne C, Pareek M, Biering-Soerensen T, Vaduganathan M, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2732. DOI: 10.1093/ehjci/ehaa946.2732.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressure loweringBlood pressure loweringSerum potassium levelsIntensive blood pressureSerum potassiumPressure loweringPotassium levelsCV causesMultivariable adjustmentBlood pressureSystolic blood pressure 130End-stage renal diseaseBaseline serum potassiumLong-time mortalityShort-time mortalityStandard antihypertensive treatmentHigh cardiovascular riskHigh-risk patientsGlomerular filtration rateYears of ageSerum potassium measurementsAntihypertensive treatmentCardiovascular riskRenal function